Romidepsin for the treatment of peripheral t-cell lymphoma

Swaminathan P. Iyer, Francine F. Foss

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas associated with poor prognosis in most subtypes. Diagnosis of this rare disease by expert hematopathologists improves accuracy of subtyping, and referral to academic or specialty centers is recommended. Many patients, however, will receive treatment in the community, and knowledge of approved agents is key to optimizing therapeutic approaches for all patients. There is no current standard ofcare for patients with PTCL and no approved therapies for first-line treatment. Although many patients initially respond to induction chemotherapy, responses are often brief, and many patients relapse or become treatment refractory. For patients with relapsed or refractory PTCL, achievement of durable responses is challenging, and there are few treatment options. Romidepsin is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with cutaneous T-cell lymphoma who have received one prior systemic therapy or more and patients with PTCL who have received one prior therapy or more. Approval of romidepsin for PTCL was based on a pivotal phase II study of patients with relapsed or refractory PTCL (n 5 131) that demonstrated an objective response rate of 25% including 15% with complete response; responses lasted a median of.2 years. Long-term responses to romidepsin were achieved in patients regardless of baseline characteristics, including subtype, heavy pretreatment, response to prior therapy, or advanced disease. Common adverse events included hematologic abnormalities, gastrointestinal or asthenic conditions, and infections; romidepsin was not correlated with clinically meaningful QT prolongation or electrocardiogram abnormalities.

Original languageEnglish (US)
Pages (from-to)1084-1091
Number of pages8
Issue number9
StatePublished - Jun 22 2015


  • Lymphoma
  • Peripheral
  • Romidepsin
  • T cell

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Romidepsin for the treatment of peripheral t-cell lymphoma'. Together they form a unique fingerprint.

Cite this